Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Gross Profit (2017 - 2025)

Puma Biotechnology's Gross Profit history spans 9 years, with the latest figure at $52.3 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 15.88% year-over-year to $52.3 million; the TTM value through Dec 2025 reached $170.2 million, up 2.5%, while the annual FY2025 figure was $170.2 million, 2.5% up from the prior year.
  • Gross Profit reached $52.3 million in Q4 2025 per PBYI's latest filing, up from $42.3 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $70.8 million in Q4 2022 to a low of $33.0 million in Q1 2024.
  • Average Gross Profit over 5 years is $44.7 million, with a median of $42.8 million recorded in 2023.
  • The largest YoY upside for Gross Profit was 62.92% in 2022 against a maximum downside of 49.15% in 2022.
  • A 5-year view of Gross Profit shows it stood at $43.5 million in 2021, then surged by 62.92% to $70.8 million in 2022, then crashed by 32.42% to $47.9 million in 2023, then decreased by 5.64% to $45.2 million in 2024, then increased by 15.88% to $52.3 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Gross Profit are $52.3 million (Q4 2025), $42.3 million (Q3 2025), and $40.1 million (Q2 2025).